Agendia Inc. aims to use artificial intelligence to enhance its breast cancer diagnostic tests.Â
The Irvine-based test maker, which has raised nearly $200 million since its 2003 inception, said late last month it would work with N.Y.-based digital pathology firm Paige to develop new planning tools and products for its customers.
Oncologists and cancer patients use Agendia’s MammaPrint and BluePrint genomic profiling tests to make personalized treatment decisions.
Paige is the first and only firm to receive federal clearance for a digital pathology platform; its AI software allows physicians to view tissue images on imaging scanners.
“Paige has paved a way for artificial intelligence to have a compelling role in driving diagnostic confidence in pathology,” Mark Straley, chief executive of Agendia, told the Business Journal via email.
“We believe paired with Agendia’s arsenal of genomic profiling capabilities, we can collectively create treatment planning tools that will provide pathologists and oncologists with faster and greater access to predictive and prognostic information to guide their patients’ care.”
The partnership will decrease time to results because no tissue will be required to perform testing, only a digitized image, as well as increase access to results for physicians and patients in countries with limited capabilities or that do not allow tissue samples to be sent out of the country.
The partnership is the first of two that are expected to broaden Agendia’s reach across the entire cancer treatment life cycle, Straley told the Business Journal in August.
